JAMA
Original Investigation
April 24, 2024
CynthiaÌýGyamfi-Bannerman,ÌýMD, MS; Rebecca G.ÌýClifton,ÌýPhD; Alan T. N.ÌýTita,ÌýMD, PhD; Sean C.ÌýBlackwell,ÌýMD; MonicaÌýLongo,ÌýMD, PhD; Jessica A.Ìýde Voest,ÌýPhD; T. MichaelÌýO’Shea,ÌýMD, MPH; Sabine Z.ÌýBousleiman,ÌýMSN, MSPH; FeleciaÌýOrtiz,ÌýRN, BSN; Dwight J.ÌýRouse,ÌýMD; Torri D.ÌýMetz,ÌýMD, MS; George R.ÌýSaade,ÌýMD; Kara M.ÌýRood,ÌýMD; Kent D.ÌýHeyborne,ÌýMD; John M.ÌýThorpÌýJr,ÌýMD; Geeta K.ÌýSwamy,ÌýMD; William A.ÌýGrobman,ÌýMD, MBA; Kelly S.ÌýGibson,ÌýMD; Yasser Y.ÌýEl-Sayed,ÌýMD; George A.ÌýMacones,ÌýMD, MSCE; Eunice Kennedy Shriver Maternal-Fetal Medicine Units Network
is active quiz
JAMA. 2024; 331(19):1629-1637. 10.1001/jama.2024.4303
This prospective follow-up study of a randomized clinical trial evaluates whether antenatal corticosteroids administered to birthing parents at risk of late preterm delivery were associated with adverse neurodevelopmental effects on their offspring.